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Heart failure with preserved ejection fraction (HFpEF) now accounts for the majority of con-
firmed HF cases in the United States. However, there are no highly effective evidence-based
treatments currently available for these patients. Inflammation correlates positively with
adverse outcomes in HF patients. Interleukin (IL)-1, a prototypical inflammatory cytokine, has
been implicated as a driver of diastolic dysfunction in preclinical animal models and a pilot clini-
cal trial. The Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2) is a phase 2, 2:1 ran-
domized, double-blind, placebo-controlled clinical trial that will test the hypothesis that IL-1
blockade with anakinra (recombinant human IL-1 receptor antagonist) improves (1) cardiorespi-
ratory fitness, (2) objective evidence of diastolic dysfunction, and (3) elevated inflammation in
patients with HFpEF (http://www.ClinicalTrials.gov NCT02173548). The co–primary endpoints
will be placebo-corrected interval changes in peak oxygen consumption and ventilatory effi-
ciency at week 12. In addition, secondary and exploratory analyses will investigate the effects
of IL-1 blockade on cardiac structure and function, systemic inflammation, endothelial function,
quality of life, body composition, nutritional status, and clinical outcomes. The D-HART2 clinical
trial will add to the growing body of evidence on the role of inflammation in cardiovascular dis-
ease, specifically focusing on patients with HFpEF.
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1 | INTRODUCTION
Patients with heart failure (HF) and a preserved left ventricular
(LV) ejection fraction (HFpEF) comprise >50% of the overall HF popu-
lation.1 The management of HFpEF represents a significant challenge,
as currently available therapies do not significantly improve exertional
dyspnea, exercise tolerance, or survival.1
Evidence of the presence of heightened inflammation is well
established in HF.2 Interleukin-1 (IL-1), an apical cytokine, was iso-
lated first by Dinarello and colleagues as a leukocytic pyrogen factor.3
Subsequent investigations have shown that IL-1 is a master regulator
not only of fever, but also of a complex humoral and cellular inflam-
matory response.3Clinicaltrials.gov Identification Number: NCT02173548
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In addition to its role in systemic inflammation, early investiga-
tions noted that IL-1 was a soluble cardiodepressant factor in septic
shock.4 This initial clinical observation has led to a deeper under-
standing of IL-1’s effects on the myocardium, including impairment of
cardiac diastolic function, a hallmark of HFpEF, through modulation
of sarcoplasmic reticulum phospholamban and calcium-ATPase.2,5
In experimental models, the administration of IL-1 to healthy
mice increases isovolumetric relaxation time and LV end-diastolic
pressure, impairs LV − dP/dT, and induces chronotropic incompe-
tence.6,7 IL-1 blockade prevents and restores diastolic dysfunction in
a murine heart failure model.7 (For a summary of the effects of IL-1
on myocardial structure and function, see Supporting Information,
Figure 1, in the online version of this article.)
IL-1 hyperactivity in patients with HF is supported by a large
body of clinical evidence.8–10 Moreover, C-reactive protein (CRP),
which is considered a marker of IL-1 activity, correlates positively
with LV end-diastolic pressure11 as well as peak oxygen consumption
(VO2) and ventilatory efficiency—both prognostic indicators in HF.
12
Importantly, IL-1 blockade is distinct from tumor necrosis factor-
α (TNF-α) inhibition.2 IL-1 and TNF-α are distinct cytokines, regulated
by different families of genes, different families of receptors, and dif-
ferent signaling cascades. IL-1, in its 2 isoforms (IL-1α and IL-1β),
binds a single signaling membrane receptor (IL-1R) that is part of the
Toll-IL-1 family of receptors.3 In contrast, TNF-α binds one of 2 mem-
brane receptors, type I and type II, that are part of a large family of
receptors called the TNF-α superfamily of receptors, which includes
≥27 subtypes that share the ability to bind the ligand via an extracel-
lular cysteine-rich domain and include many death-ligand receptors.13
The 2 TNF-α receptors have different, and often opposing, down-
stream signaling.14 Moreover, TNF-α inhibition causes immunosup-
pression and has a nonlinear dose-response relationship; IL-1
blockade does not appear to have these limitations.2
Based on these data, the Diastolic Heart Failure–Anakinra
Response Trial (D-HART, http://www.ClinicalTrials.gov
NCT01542502), a randomized, double-blind, placebo-controlled
crossover study of 12 patients with HFpEF and objective diastolic
dysfunction, was conducted.15 Patients with stable HFpEF and heigh-
tened systemic inflammation (high-sensitivity CRP [hsCRP] >2 mg/L)
were eligible. Patients were treated with anakinra 100 mg daily for
14 days or placebo, followed by crossover to the other
treatment arm.
Treatment with anakinra (Kineret; Swedish Orphan Biovitrum,
Stockholm, Sweden), a recombinant nonglycosylated human IL-1
receptor antagonist, for 14 days provided a placebo-corrected inter-
val change in peak VO2 of +1.1 mL•kg
−1•min−1 (Figure 1).15 CRP was
reduced by 84% during the 14 days of anakinra treatment, and
changes in CRP correlated significantly with changes in peak VO2.
Oxygen uptake efficiency slope, a measure of ventilatory efficiency,
significantly improved during anakinra treatment. The minute
ventilation–carbon dioxide production slope, another measure of ven-
tilatory efficiency, was abnormal in 5 of the 12 patients at baseline
and significantly improved with anakinra treatment.
We designed the D-HART2 trial to confirm the effects of ana-
kinra on cardiorespiratory fitness (CRF) and inform the design of a
larger outcomes trial.
2 | METHODS
2.1 | Study design and oversight
The D-HART2 trial (http://www.ClinicalTrials.gov NCT02173548) is a
single-center, randomized, double-blind, phase 2 clinical trial with 2:1
allocation to anakinra or placebo, designed to investigate the effects
of IL-1 blockade on CRF and cardiac structure and function in
patients with symptomatic HFpEF (New York Heart Association class
II–III), confirmed diastolic dysfunction, and evidence of systemic
inflammation (Figure 2). Exploratory analyses of body composition,
FIGURE 1 Effects of IL-1 blockade on
cardiorespiratory fitness in a pilot clinical
trial. A randomized, double-blind,
crossover, pilot study evaluated the effects
of IL-1 blockade in patients with HFpEF.
Abbreviations: HFpEF, heart failure with
preserved ejection fraction; IL-1,
interleukin 1; peak VO2, peak oxygen
consumption; VE/VCO2, minute
ventilation–carbon dioxide production
relationship
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nutritional status, circulating biomarkers (except hsCRP, which is a
secondary endpoint), and vascular function will also be conducted.
The Clinical Event Committee is composed of Michael Kontos,
MD (chair), Keyur Shah, MD, and Jaideep Patel, MD. The Data and
Safety Monitoring Board includes Dominick Angiolillo, MD (chair),
Richard Cooke, MD, Gonzalo Bearman, MD, Ion Jovin, MD, Jeffrey
Kushinka, MD, and Christine DeWilde, RN (coordinator). For a com-
plete list of study personnel, see Supporting Information, Appendix,
in the online version of this article.
2.2 | Screening and enrollment
Patients are eligible for inclusion (Table) if they have signs and symptoms
of HF and objective confirmation of LV ejection fraction >50%, diastolic
dysfunction or elevated LV filling pressure,16 and hsCRP ≥2 mg/L.
The initial inclusion criteria required a previous hospitalization for
HF. In light of the fact that such criterion is no longer considered to
be a reliable marker of HF severity, this criterion was subsequently
removed to facilitate patient enrollment.17 Twenty patients had been
enrolled prior to the removal of the previous-hospitalization criterion.
Major exclusion criteria (Table) include (1) an inability to com-
plete or a contraindication to maximal cardiopulmonary exercise test-
ing (CPET); (2) any auto-inflammatory or autoimmune disease; and
(3) chronic, long-term treatment with an anti-inflammatory or immu-
nosuppressant agent.
2.3 | Randomization and allocation concealment
The randomization log was prepared by an outside consultant and
sent electronically to the director of the investigational pharmacy at
Virginia Commonwealth University. Investigators were blinded to all
CRP levels during the study. Identical anakinra or placebo syringes
were dispensed by the investigational pharmacy.
2.4 | Study treatment
Patients were randomized 2:1 to either anakinra (Kineret) 100 mg or
placebo, administered once daily for 12 weeks. The primary side
effects of anakinra are injection-site reactions, such as erythema or
pain. By blocking IL-1, anakinra prevents fever and other systemic
manifestation of disease, and as such it may delay the diagnosis of
infection.
Patients in the study will receive standard-of-care medical treat-
ments, such as diuretics, β-adrenergic receptor blockers, angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers, aldos-
terone blockers, isosorbide dinitrate, hydralazine, digoxin, aspirin, and
statins.
2.5 | Endpoints
Placebo-controlled interval changes in peak VO2 and the minute ven-
tilation (VE)/VCO2 slope after 12 weeks of treatment with anakinra
or placebo are the co–primary endpoints (see Supporting Information,
Table 1, in the online version of this article).
Secondary CPET endpoints include interval changes in peak VO2
and VE/VCO2 slope at 4 and 24 weeks, as well as the oxygen uptake
efficiency slope, anaerobic threshold, and chronotropic response (see
Supporting Information, Table 1, in the online version of this article).
Structural and functional myocardial parameters captured with
transthoracic echocardiography according to current guidelines
include left and right ventricular and atrial dimensions, left and right
ventricular systolic function, transmitral flow Doppler spectra, mitral
and tricuspid valve annulus tissue Doppler spectra, ejection time,
stroke volume, inferior vena cava, and aorta and pulmonary artery
diameters and Doppler spectra.18 Patients also undergo a limited
stress echocardiography and Doppler study immediately after peak
exercise at baseline and 12 weeks to measure placebo-controlled
interval changes in diastolic reserve measured as changes in E/e´
ratio with exercise.
Blood will be analyzed for complete blood count, metabolic mar-
kers (including lipids and lipoproteins, glycemic control and insulin
resistance, hepatic and renal panels, sterols), inflammation (hsCRP,
galectin-3), and cardiac biomarkers (N-terminal pro-brain natriuretic
peptide and troponin I). Galectin-3, an established prognostic marker
in HF and a surrogate for fibrosis, was included given the importance
of fibrotic adverse LV remodeling and to investigate its potential rela-
tionship to inflammation.19 With the exception of hsCRP, biomarker
assessments are considered exploratory.
Clinical endpoints will include death (cardiac and noncardiac),
hospitalizations (cardiac, including HF and non-HF and noncardiac),
and serious and nonserious adverse events through study conclusion
or 108 weeks, whichever occurs last. Detailed definitions of each
endpoint are provided in Supporting Information, Table 2, in the
online version of this article.
Dietary assessment and body-composition analysis will be con-
ducted by trained dietitians using a standardized 24-hour dietary
recall method and bioelectrical impedance analysis, respectively.
2.6 | Cardiopulmonary exercise testing
A physician-supervised maximal CPET will be administered using a
metabolic cart interfaced with a treadmill. A standard conservative
ramping treadmill protocol is used as previously reported and
FIGURE 2 Design of the Diastolic Heart Failure–Anakinra Response
Trial 2 (D-HART2). Abbreviations: CPET, cardiopulmonary exercise
testing; echo, echocardiography; HFpEF, heart failure with preserved
ejection fraction
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according to American Heart Association guidelines.20–22 All patients
must achieve a respiratory exchange ratio >1.00, and preferably
>1.10. Tests were repeated if a patient did not achieve a maximal
effort.
The highest 10-second average value within the 30 seconds prior
to study completion for O2 uptake defines peak VO2 in
mL•kg−1•min−1. The dual-methods criteria wherein the V-slope
method and the ventilatory equivalents method will be employed to
determine VO2 at ventilatory threshold (VAT). Ten-second averaged
VE and VCO2 data, from the initiation of exercise to peak, will be uti-
lized to calculate the VE/VCO2 slope via least squares linear regres-
sion (y = mx + b, m = slope). Chronotropic response will be
determined from the chronotropic index, which is the difference
between the peak heart rate (HR) and the resting HR relative to the
metabolic requirement of exercise (peak VO2 − resting VO2).
2.7 | Symptom assessment
Patient-reported symptoms will be assessed at each study visit. The
Minnesota Living with Heart Failure Questionnaire (MLHFQ) is a 21-
item graded questionnaire that has been extensively used to measure
impairment in quality of life in patients with HF.23 The Duke Activity
Status Index (DASI) is a 12-item instrument that allows for the calcu-
lation of perceived functional capacity, in which each question
describes a different physical activity and the questions are weighted
according to their degree of physical exertion.24
2.8 | Bioelectrical impedance analysis
Body-composition assessment will be conducted at each visit with
bioelectrical impedance analysis, a noninvasive, quick, and safe
technique that allows for an accurate estimation of fluid status and
body composition. Two electrodes on the foot and 2 on the homolat-
eral hand (superior limbs abducted at 30 and inferior limbs at 45)
measure electrical signals with a Quantum IV Body Composition Ana-
lyzer (RJL Systems, Clinton Township, MI). Body composition (total
body water, extracellular water, intracellular water, lean fat-free mass,
and fat mass) will be calculated using dedicated software.
2.9 | Vascular assessment
As an exploratory analysis, vascular assessment was conducted at
each study visit. A small plethysmography cuff (ccNexfin; Edwards
Lifesciences, Irvine, CA) will be placed on the subject’s finger to
measure blood flow. After capture of baseline variables, a standard
blood pressure (BP) cuff will then be placed on the arm and inflated
for 3 minutes. The finger cuff will measure baseline and change in
BP, HR, estimated cardiac output, and systemic vascular resistance.
Reactive hyperemia will be calculated as the highest 10-second aver-
age cardiac output within 3 minutes post-deflation divided by base-
line cardiac output. Flow-mediated dilatation will be estimated from
reactive hyperemia using Poiseuille’s law. Effective arterial elastance
and end-systolic elastance will be calculated as previously reported.25
2.10 | Safety assessment
Safety parameters will include data deriving from history and physical
examination performed at each visit, laboratory data, and results of
functional and imaging tests. To enhance detection of adverse events
between visits, all patients will be encouraged to contact the research
team at any time with concerns or any perceived changes in their
TABLE 1
Inclusion Criteria (all must be present) Exclusion Criteria
• Symptoms and signs of heart failure (NYHA II-III)
• Recent imaging study (<12 months) showing LVEF>50% and
LVEDVI<97ml/m2
• Evidence of abnormal LV relaxation, filling, diastolic distensibility and
diastolic stiffness as shown by one of the following invasive
hemodynamic measurements, tissue Doppler echocardiography or
biomarker: invasive hemodynamic measurements (mPCWP >12 or
LVEDP>16mmHg); tissue Doppler echocardiography (E/e’ >15 or E/e’ 8-
15 and one of LVH, LAE or E/A<0.5+DT>280); BNP >200pg/mL (not
due to a concomitant disease such as pulmonary arterial hypertension,
pulmonary embolism, acute renal failure, or other)
• hsCRP > 2.0 mg/L
• Age <21 years
• Concomitant conditions or treatments which would affect completion
of the study or interpretation of the study tests including but not
limited to the following conditions: physical inability to walk or run on a
treadmill; angina or evidence of spontaneous or inducible ischemia;
uncontrolled arterial hypertension; atrial fibrillation (or other
arrhythmias); moderate to severe valvular heart disease; chronic
pulmonary disease; anemia (Hgb<10 g/dl)
• Angina, uncontrolled hypertension or electrocardiograph (ECG) changes
(i.e. ischemia, arrhythmias) that limit maximum exertion during
cardiopulmonary exercise testing
• Anticipated need for surgery
• Active infection including chronic infection
• Active cancer (or prior diagnosis of cancer within the past 10 years)
• Recent (<14 days) or active use of immunosuppressive drugs (including
but not limited to high-dose corticosteroids [>1 mg/kg of prednisone
equivalent], TNF-α blockers, cyclosporine) not including NSAIDs or
corticosteroids used for IV dye allergy only)
• Chronic auto-immune or auto-inflammatory disease (including but not
limited to rheumatoid arthritis, systemic lupus erythematosus)
• Neutropenia (absolute neutrophil count<1,800/mm3 [or <1,000/mm3 in
African-American patients])
• Severe impairment in renal function (estimated glomerular filtration
rate <30 ml/kg*min)
• Recent or planned use of vaccination with live attenuated viruses
• Allergy to rubber or latex
• Allergy to products derived from Escherichia coli
• Pregnancy or breastfeeding
• Inability to give informed consent
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clinical status. Particular attention will be given toward symptoms
and signs of infection.
2.11 | Statistical analysis
The CPET data will be collected and electronically transferred to the
Core Laboratory at the University of Illinois at Chicago for analysis,
under the guidance of Ross Arena, PhD. After locking the database,
Dr. Arena will be provided a group allocation according to treatment
A or B (blinded to real treatment). Data will then be analyzed accord-
ing to blinded group allocation and the description of the true group
allocation will be disclosed only after completion of the analysis. All
other data will be analyzed at VCU in an identical fashion. For all end-
points, an unadjusted P value of <0.05 will be considered statistically
significant.
2.11.1 | Sample size calculation
The sample size for this pilot study was calculated according to the
primary endpoint of difference in interval change in peak VO2 at
12 weeks between anakinra and placebo. The initial calculation based
on an expected average peak VO2 of 15  3.5 mL•kg−1•min−1, and
randomization of 40 subjects to anakinra and 20 subjects to placebo
indicated >99%, >99%, 99%, and 86% power to detect a difference in
peak VO2 of 3.5, 3.0, 2.5, and 2.0 mL•kg
−1•min−1 in peak VO2,
respectively.
In October 2016, given a slower than expected enrollment rate,
the investigators reviewed the baseline data and original power calcu-
lations. Data from prior HF clinical trials of CPET26–29 and our own
preliminary data15 suggested that a more accurate expected SD for
within-subject changes is 1.9 mL•kg−1•min−1, as opposed to the orig-
inal 3.5 mL•kg−1•min−1 (see Supporting Information, Figure 2, in the
online version of this article). Based on this new estimate of variance,
enrollment of 30 patients in the same 2:1 ratio would retain >99%,
90%, and 78% power to detect a minimum difference in peak VO2 of
3.5, 3.0, and 2.0 mL•kg−1•min−1. The sample size was adjusted to
30 patients.
2.11.2 | Demographics and baseline characteristics
Baseline measurements and demographic characteristics will be sum-
marized for the patients in each of the treatment arms. Descriptive
summaries of continuous measurements will consist of medians and
interquartile ranges due to potential deviation from Gaussian distribu-
tion. Descriptive summaries of categorical measurements will consist
of frequencies, proportions, and 95% confidence intervals on those
proportions. Baseline characteristics for treatment and control groups
will be compared with the χ2 test for categorical variables or the
Mann-Whitney U test for continuous variables.
2.11.3 | Endpoint Analysis
The analysis will be performed at the conclusion of the study as
described above. The interval change between treatment groups will
be compared using random effects analysis of variance (ANOVA) for
repeated measures assessing for the interaction between “time” and
“group allocation.” For clinical events, Kaplan-Meier curves will be
constructed and compared using log-rank testing. The primary
analysis for all endpoints will be conducted in a modified intention-
to-treat population, which includes all patients who were randomized
and have complete data for the primary endpoints at baseline and
12 weeks or have complete data at baseline and at 4 weeks, in which
case the 4-weeks value will be used according to the last-observa-
tion-carried-forward principle.
A landmark analysis will be performed as an on-treatment and
off-treatment analysis in which the Kaplan-Meier curves created for
patients treated with placebo and anakinra are compared for the first
12 weeks (on-treatment) and separately for the following 12 weeks
(off-treatment) using the log-rank test for event rates to assess for
the potential loss of benefit with cessation of treatment.
In addition, a sensitivity analysis will be conducted after stratifi-
cation of patients according to presence or absence of prior
hospitalization.
3 | RESULTS
Preliminary results: The first patient was enrolled on September
3, 2014. DHART2 has completed enrollment of the 30 patients, and
the last patient’s last visit is on June 20, 2017.
4 | DISCUSSION
A significant link between increased IL-1 activity and outcomes in
patients with HF has been established. The D-HART2 study is testing
whether IL-1 blockade improves the co–primary endpoints of peak
VO2 and ventilatory efficiency in patients with symptomatic HFpEF,
evidence of impaired diastolic function, and heightened systemic
inflammation. Because effective treatment options for HFpEF are lim-
ited, IL-1 blockade may fill an important unmet medical need.
Prior HFpEF clinical trials have failed to demonstrate significant
improvements in clinical outcomes. One explanation for these disap-
pointing results is that HFpEF itself is a heterogeneous syndrome
with multiple subphenotypes of varying etiology and pathophysiol-
ogy. Enrollment of a broad cohort, as conducted in prior studies, may
have diluted any potential signal of benefit. Similarly, HFpEF symp-
toms can be mimicked by other conditions, suggesting the need for
inclusion criteria that identify structural and/or functional myocardial
impairment.
Thus, D-HART2 was designed with strict inclusion criteria to
ensure the enrollment of a homogenous cohort of patients who had
both impaired cardiac diastolic function and reduced exercise capac-
ity. Supporting Information, Table 3, in the online version of this arti-
cle compares eligibility criteria across HFpEF clinical trials that
utilized CPET as an endpoint. Slow enrollment in DHART2 can likely
be attributed to these strict criteria. The best approach for the design
of future HFpEF clinical trials likely represents a hybrid of the
2 approaches discussed here.
The co–primary endpoints were selected on the basis that they
each correlate significantly with mortality in HF and provide a func-
tional assessment of exercise capacity—sufficient justification for sub-
sequent clinical trials.30–32 Moreover, these outcomes are ideal
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surrogates for a phase 2 trial, as they are immune to bias from over-
exertion, show minimal training effects over time, and exhibit high
intraclass correlation coefficients (>0.90).26,33–37 Assessment of clini-
cal outcomes will further provide possible justification for future clini-
cal trials.
The D-HART2 trial will also provide insight into possible mechan-
isms through which IL-1 affects cardiac function. Doppler echocardiog-
raphy will aid in determining the effects of IL-1 blockade on cardiac
structure and function. An important assessment will be the effects of
IL-1 blockade on early diastolic E wave deceleration time and E´ mitral
annular velocity, measures of active relaxation, both at rest and at peak
exercise.38 Estimates of flow-mediated dilatation will evaluate whether
IL-1 blockade affects endothelial function. Recent studies have sug-
gested that ventricular-arterial uncoupling plays an important role in the
syndrome of HFpEF.39 Measurement of CRP will be utilized to confirm
that adequate inflammation suppression was achieved and to determine
if improvements in CRF correlate with changes in inflammation.
There is growing appreciation for the interaction between total
body weight, total fat mass, and inflammation in HFpEF.40 In fact,
one study demonstrated improvements in peak VO2 after caloric
restriction with or without a structured exercise program in obese
HFpEF patients despite no change in measures of diastolic func-
tion.29 The dietary recall and body composition assessments will fur-
ther support novel hypotheses on the relationship between specific
dietary components (ie, mono- or polyunsaturated fatty acids) and
HFpEF.
4.1 | Study limitations
There are potential limitations to the design of D-HART2, many of
which are inherent to pilot clinical trials. Secondary outcomes will be
considered hypothesis-generating, and the study is not intended to
evaluate clinical outcomes such as hospitalizations or mortality.
Results may not be applicable to other centers with different HF
management practices due to the single-center design. It will remain
unclear whether patients with hsCRP < 2 mg/L would also benefit
from anakinra. At present, in the D-HART pilot trial, 14 of 23 patients
(60%) who were screened for eligibility had an hsCRP >2 mg/dL.
5 | CONCLUSION
The D-HART2 pilot trial will test the novel hypothesis that IL-1
impairs CRF in patients with HFpEF. The data collected with CPET,
echocardiography, and clinical assessment will inform the design of
potential larger studies aimed at assessing the effects of IL-1 block-
ade on clinical outcomes. This pilot trial adds to the current portfolio
of ongoing clinical trials that are currently assessing the role of IL-1 in
acute myocardial infarction, prior myocardial infarction, systolic HF,
systolic HF in end-stage renal disease, and pericarditis.
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